Palvella Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Palvella Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Palvella Therapeutics Inc.
Rating: 1.78050
Author: Trendlyne DVM scores

about

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapa...

99.73 -4.25 (-4.09%)

716.79% Gain from 52W Low

252.8K

XNAS Volume

XNAS 16 Jan, 2026 4:30 PM (EST)

Not Eligible

Expensive Valuation

1.0 / 100

Technically Bullish

70.2 / 100

No estimates available

Palvella Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Palvella Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapa...

716.79% Gain from 52W Low

SWOT Analysis

Palvella Therapeutics Inc Live Price Chart